Sexual health after breast cancer: a clinical practice review
SKF Kennedy, S Mekhaeil… - Annals of …, 2024 - researchnow.flinders.edu.au
Breast cancer (BC) diagnoses not only present physical challenges but profoundly affect
survivors' psychosocial well-being leading to sexual health challenges. This clinical practice …
survivors' psychosocial well-being leading to sexual health challenges. This clinical practice …
New potential selective estrogen receptor modulators in traditional Chinese medicine for treating menopausal syndrome
X Song, L Shen, JM Contreras, Z Liu, K Ma… - Phytotherapy …, 2024 - Wiley Online Library
Women go through several predictable conditions and symptoms during menopause that
are caused by age, changes in sex hormone levels, and other factors. Conventional …
are caused by age, changes in sex hormone levels, and other factors. Conventional …
[HTML][HTML] Safety of topical estrogen therapy during adjuvant endocrine treatment among patients with breast cancer: A meta-analysis based expert panel discussion
SL Kastora, E Pantiora, YH Hong, M Veeramani… - Cancer Treatment …, 2025 - Elsevier
Importance Endocrine treatments, such as Tamoxifen (TAM) and/or Aromatase inhibitors
(AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These …
(AI), are the adjuvant therapy of choice for hormone-receptor positive breast cancer. These …
Effects of vaginal estrogen on serum estradiol during aromatase inhibitor therapy in breast cancer patients with vulvovaginal atrophy: a prospective trial
M Faltinová, L Vehmanen, H Lyytinen… - Breast Cancer Research …, 2024 - Springer
Purpose This study aimed to analyze changes in serum estradiol (E2) levels during
concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast …
concurrent vaginal estradiol therapy and adjuvant letrozole in postmenopausal breast …
The Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO
MR Cordeiro, B Laranjeiro… - International Journal of …, 2024 - mdpi.com
Risk-reducing bilateral sal**o-oophorectomy (RRSO) is recommended for breast cancer
gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is …
gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is …
[HTML][HTML] Development and Bioavailability Assessment of an Estriol-Containing Vaginal Hydrogel
Genitourinary syndrome of menopause (GSM) affects a significant percentage of
postmenopausal women and manifests as vaginal dryness, irritation, and urinary discomfort …
postmenopausal women and manifests as vaginal dryness, irritation, and urinary discomfort …
Vaginal Estrogen Use in Breast Cancer Survivors: A Systematic Review and Meta-Analysis of Recurrence and Mortality Risks
ME Beste, AM Kaunitz, JA McKINNEY… - American Journal of …, 2024 - Elsevier
Objective To assess the risk of breast cancer recurrence, breast cancer-specific mortality,
and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for …
and overall mortality for breast cancer survivors receiving vaginal estrogen therapy for …
Perimenopause: A Dive Into Women's Health
B Yingngam - Utilizing AI Techniques for the Perimenopause to …, 2024 - igi-global.com
Perimenopause occurs prior to menopause and manifests as physiological and psychic
changes. However, there is a substantial deficit of data and societal information concerning …
changes. However, there is a substantial deficit of data and societal information concerning …
Terapia vaginal estrogênica no tratamento de síndrome geniturinária da menopausa em pacientes com histórico de câncer de mama: revisão sistemática e …
GML Santos - 2024 - lume.ufrgs.br
O câncer de mama é o tumor mais comum entre mulheres. O aumento da sobrevivência
após o tratamento dessa doença traz desafios à qualidade de vida, especialmente devido à …
após o tratamento dessa doença traz desafios à qualidade de vida, especialmente devido à …